Global Alzheimers Disease Therapeutics Market 2018 by Manufacturers, Countries, Type and Application, Forecast to 2023

August 2018 | 122 pages | ID: G4A35E1F9C1GEN
GlobalInfoResearch

Abstracts

Alzheimer?s disease is a neurodegenerative, progressive, non-reversible disorder. Alzheimer?s disease is caused due to abnormal functioning of brain cells i.e. failure of synaptic transmission, resulting in the loss of cognitive functions. Some of the signs and symptoms of alzheimer?s disease are memory loss, insomnia, repetitive movements, agitation, anxiety, depression and loss of reasoning abilities. All memory and mental functioning may be lost in advanced stages of the disease. Alzheimer?s disease may lead to death. According to National Institute of Aging, Alzheimer?s disease is the common form of dementia.

SCOPE OF THE REPORT:

This report studies the Alzheimers Disease Therapeutics market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Alzheimers Disease Therapeutics market by product type and applications/end industries.
Population aging across the globe is a major factor driving the market for Alzheimer?s therapeutics and diagnostics. Rising life expectancy is contributing to quick increases in number of aged population, and is associated with increased prevalence of chronic diseases like dementia. Therapies for AD offer temporary and uncertain improvements in the well-being of individuals, and none of the approved drugs can modify the course of the disease advancement. Thus, the magnitude of the affected population and lack of suitable and effective treatment offers an incredible opportunity for drug manufacturers. However, identification of the primary reasons and mechanisms involved in AD are is limited. Drug manufacturers have been unable to validate significant clinical benefits of treatment for a numerous of new compounds due to strict regulations. One of the significant trend observed in this market is collaboration of the existing players. Precisely, diagnostic technology companies are carefully trying to bring about effective biomarker technologies to support and improve the drug development process for potential drug candidates which is further expected to propel the demand.
North America dominates the global market for alzheimer?s disease therapeutics due to large number of aging population. Asia followed by the Europe are expected to show high growth rates in the next five years in the global alzheimer?s disease therapeutics market. China and India are expected to be the fastest growing alzheimer?s disease therapeutics markets in Asia-Pacific region. Some of the key driving forces for alzheimer?s disease therapeutics market in emerging countries are increasing R&D investment, large pool of patients and improvement of healthcare infrastructure.
The global Alzheimers Disease Therapeutics market is valued at xx million USD in 2017 and is expected to reach xx million USD by the end of 2023, growing at a CAGR of xx% between 2017 and 2023.

The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.

North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Alzheimers Disease Therapeutics.

Europe also play important roles in global market, with market size of xx million USD in 2017 and will be xx million USD in 2023, with a CAGR of xx%.

Market Segment by Companies, this report covers

• F. Hoffmann-La Roche
• Merck
• Pfizer
• Novartis
• Eisai
• Actavis
• Daiichi Sankyo

Market Segment by Regions, regional analysis covers

• North America (United States, Canada and Mexico)
• Europe (Germany, France, UK, Russia and Italy)
• Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
• South America (Brazil, Argentina, Colombia)
• Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Market Segment by Type, covers

• Biomarkers
• Cholinesterase Inhibitors
• NMDA Receptor Antagonists

Market Segment by Applications, can be divided into

• Hospitals
• Clinics

Contents

1 ALZHEIMERS DISEASE THERAPEUTICS MARKET OVERVIEW

1.1 Product Overview and Scope of Alzheimers Disease Therapeutics
1.2 Classification of Alzheimers Disease Therapeutics by Types
  1.2.1 Global Alzheimers Disease Therapeutics Revenue Comparison by Types (2017-2023)
  1.2.2 Global Alzheimers Disease Therapeutics Revenue Market Share by Types in 2017
  1.2.3 Biomarkers
  1.2.4 Cholinesterase Inhibitors
  1.2.5 NMDA Receptor Antagonists
1.3 Global Alzheimers Disease Therapeutics Market by Application
  1.3.1 Global Alzheimers Disease Therapeutics Market Size and Market Share Comparison by Applications (2013-2023)
  1.3.2 Hospitals
  1.3.3 Clinics
1.4 Global Alzheimers Disease Therapeutics Market by Regions
  1.4.1 Global Alzheimers Disease Therapeutics Market Size (Million USD) Comparison by Regions (2013-2023)
  1.4.1 North America (USA, Canada and Mexico) Alzheimers Disease Therapeutics Status and Prospect (2013-2023)
  1.4.2 Europe (Germany, France, UK, Russia and Italy) Alzheimers Disease Therapeutics Status and Prospect (2013-2023)
  1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Alzheimers Disease Therapeutics Status and Prospect (2013-2023)
  1.4.4 South America (Brazil, Argentina, Colombia) Alzheimers Disease Therapeutics Status and Prospect (2013-2023)
  1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Alzheimers Disease Therapeutics Status and Prospect (2013-2023)
1.5 Global Market Size of Alzheimers Disease Therapeutics (2013-2023)

2 MANUFACTURERS PROFILES

2.1 F. Hoffmann-La Roche
  2.1.1 Business Overview
  2.1.2 Alzheimers Disease Therapeutics Type and Applications
    2.1.2.1 Product A
    2.1.2.2 Product B
  2.1.3 F. Hoffmann-La Roche Alzheimers Disease Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.2 Merck
  2.2.1 Business Overview
  2.2.2 Alzheimers Disease Therapeutics Type and Applications
    2.2.2.1 Product A
    2.2.2.2 Product B
  2.2.3 Merck Alzheimers Disease Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.3 Pfizer
  2.3.1 Business Overview
  2.3.2 Alzheimers Disease Therapeutics Type and Applications
    2.3.2.1 Product A
    2.3.2.2 Product B
  2.3.3 Pfizer Alzheimers Disease Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.4 Novartis
  2.4.1 Business Overview
  2.4.2 Alzheimers Disease Therapeutics Type and Applications
    2.4.2.1 Product A
    2.4.2.2 Product B
  2.4.3 Novartis Alzheimers Disease Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.5 Eisai
  2.5.1 Business Overview
  2.5.2 Alzheimers Disease Therapeutics Type and Applications
    2.5.2.1 Product A
    2.5.2.2 Product B
  2.5.3 Eisai Alzheimers Disease Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.6 Actavis
  2.6.1 Business Overview
  2.6.2 Alzheimers Disease Therapeutics Type and Applications
    2.6.2.1 Product A
    2.6.2.2 Product B
  2.6.3 Actavis Alzheimers Disease Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.7 Daiichi Sankyo
  2.7.1 Business Overview
  2.7.2 Alzheimers Disease Therapeutics Type and Applications
    2.7.2.1 Product A
    2.7.2.2 Product B
  2.7.3 Daiichi Sankyo Alzheimers Disease Therapeutics Revenue, Gross Margin and Market Share (2016-2017)

3 GLOBAL ALZHEIMERS DISEASE THERAPEUTICS MARKET COMPETITION, BY PLAYERS

3.1 Global Alzheimers Disease Therapeutics Revenue and Share by Players (2013-2018)
3.2 Market Concentration Rate
  3.2.1 Top 5 Alzheimers Disease Therapeutics Players Market Share
  3.2.2 Top 10 Alzheimers Disease Therapeutics Players Market Share
3.3 Market Competition Trend

4 GLOBAL ALZHEIMERS DISEASE THERAPEUTICS MARKET SIZE BY REGIONS

4.1 Global Alzheimers Disease Therapeutics Revenue and Market Share by Regions
4.2 North America Alzheimers Disease Therapeutics Revenue and Growth Rate (2013-2018)
4.3 Europe Alzheimers Disease Therapeutics Revenue and Growth Rate (2013-2018)
4.4 Asia-Pacific Alzheimers Disease Therapeutics Revenue and Growth Rate (2013-2018)
4.5 South America Alzheimers Disease Therapeutics Revenue and Growth Rate (2013-2018)
4.6 Middle East and Africa Alzheimers Disease Therapeutics Revenue and Growth Rate (2013-2018)

5 NORTH AMERICA ALZHEIMERS DISEASE THERAPEUTICS REVENUE BY COUNTRIES

5.1 North America Alzheimers Disease Therapeutics Revenue by Countries (2013-2018)
5.2 USA Alzheimers Disease Therapeutics Revenue and Growth Rate (2013-2018)
5.3 Canada Alzheimers Disease Therapeutics Revenue and Growth Rate (2013-2018)
5.4 Mexico Alzheimers Disease Therapeutics Revenue and Growth Rate (2013-2018)

6 EUROPE ALZHEIMERS DISEASE THERAPEUTICS REVENUE BY COUNTRIES

6.1 Europe Alzheimers Disease Therapeutics Revenue by Countries (2013-2018)
6.2 Germany Alzheimers Disease Therapeutics Revenue and Growth Rate (2013-2018)
6.3 UK Alzheimers Disease Therapeutics Revenue and Growth Rate (2013-2018)
6.4 France Alzheimers Disease Therapeutics Revenue and Growth Rate (2013-2018)
6.5 Russia Alzheimers Disease Therapeutics Revenue and Growth Rate (2013-2018)
6.6 Italy Alzheimers Disease Therapeutics Revenue and Growth Rate (2013-2018)

7 ASIA-PACIFIC ALZHEIMERS DISEASE THERAPEUTICS REVENUE BY COUNTRIES

7.1 Asia-Pacific Alzheimers Disease Therapeutics Revenue by Countries (2013-2018)
7.2 China Alzheimers Disease Therapeutics Revenue and Growth Rate (2013-2018)
7.3 Japan Alzheimers Disease Therapeutics Revenue and Growth Rate (2013-2018)
7.4 Korea Alzheimers Disease Therapeutics Revenue and Growth Rate (2013-2018)
7.5 India Alzheimers Disease Therapeutics Revenue and Growth Rate (2013-2018)
7.6 Southeast Asia Alzheimers Disease Therapeutics Revenue and Growth Rate (2013-2018)

8 SOUTH AMERICA ALZHEIMERS DISEASE THERAPEUTICS REVENUE BY COUNTRIES

8.1 South America Alzheimers Disease Therapeutics Revenue by Countries (2013-2018)
8.2 Brazil Alzheimers Disease Therapeutics Revenue and Growth Rate (2013-2018)
8.3 Argentina Alzheimers Disease Therapeutics Revenue and Growth Rate (2013-2018)
8.4 Colombia Alzheimers Disease Therapeutics Revenue and Growth Rate (2013-2018)

9 MIDDLE EAST AND AFRICA REVENUE ALZHEIMERS DISEASE THERAPEUTICS BY COUNTRIES

9.1 Middle East and Africa Alzheimers Disease Therapeutics Revenue by Countries (2013-2018)
9.2 Saudi Arabia Alzheimers Disease Therapeutics Revenue and Growth Rate (2013-2018)
9.3 UAE Alzheimers Disease Therapeutics Revenue and Growth Rate (2013-2018)
9.4 Egypt Alzheimers Disease Therapeutics Revenue and Growth Rate (2013-2018)
9.5 Nigeria Alzheimers Disease Therapeutics Revenue and Growth Rate (2013-2018)
9.6 South Africa Alzheimers Disease Therapeutics Revenue and Growth Rate (2013-2018)

10 GLOBAL ALZHEIMERS DISEASE THERAPEUTICS MARKET SEGMENT BY TYPE

10.1 Global Alzheimers Disease Therapeutics Revenue and Market Share by Type (2013-2018)
10.2 Global Alzheimers Disease Therapeutics Market Forecast by Type (2018-2023)
10.3 Biomarkers Revenue Growth Rate (2013-2023)
10.4 Cholinesterase Inhibitors Revenue Growth Rate (2013-2023)
10.5 NMDA Receptor Antagonists Revenue Growth Rate (2013-2023)

11 GLOBAL ALZHEIMERS DISEASE THERAPEUTICS MARKET SEGMENT BY APPLICATION

11.1 Global Alzheimers Disease Therapeutics Revenue Market Share by Application (2013-2018)
11.2 Alzheimers Disease Therapeutics Market Forecast by Application (2018-2023)
11.3 Hospitals Revenue Growth (2013-2018)
11.4 Clinics Revenue Growth (2013-2018)

12 GLOBAL ALZHEIMERS DISEASE THERAPEUTICS MARKET SIZE FORECAST (2018-2023)

12.1 Global Alzheimers Disease Therapeutics Market Size Forecast (2018-2023)
12.2 Global Alzheimers Disease Therapeutics Market Forecast by Regions (2018-2023)
12.3 North America Alzheimers Disease Therapeutics Revenue Market Forecast (2018-2023)
12.4 Europe Alzheimers Disease Therapeutics Revenue Market Forecast (2018-2023)
12.5 Asia-Pacific Alzheimers Disease Therapeutics Revenue Market Forecast (2018-2023)
12.6 South America Alzheimers Disease Therapeutics Revenue Market Forecast (2018-2023)
12.7 Middle East and Africa Alzheimers Disease Therapeutics Revenue Market Forecast (2018-2023)

13 RESEARCH FINDINGS AND CONCLUSION

14 APPENDIX

14.1 Methodology
14.2 Data Source

List Of Tables

LIST OF TABLES AND FIGURES

Figure Alzheimers Disease Therapeutics Picture
Table Product Specifications of Alzheimers Disease Therapeutics
Table Global Alzheimers Disease Therapeutics and Revenue (Million USD) Market Split by Product Type
Figure Global Alzheimers Disease Therapeutics Revenue Market Share by Types in 2017
Figure Biomarkers Picture
Figure Cholinesterase Inhibitors Picture
Figure NMDA Receptor Antagonists Picture
Table Global Alzheimers Disease Therapeutics Revenue (Million USD) by Application (2013-2023)
Figure Alzheimers Disease Therapeutics Revenue Market Share by Applications in 2017
Figure Hospitals Picture
Figure Clinics Picture
Table Global Market Alzheimers Disease Therapeutics Revenue (Million USD) Comparison by Regions 2013-2023
Figure North America Alzheimers Disease Therapeutics Revenue (Million USD) and Growth Rate (2013-2023)
Figure Europe Alzheimers Disease Therapeutics Revenue (Million USD) and Growth Rate (2013-2023)
Figure Asia-Pacific Alzheimers Disease Therapeutics Revenue (Million USD) and Growth Rate (2013-2023)
Figure South America Alzheimers Disease Therapeutics Revenue (Million USD) and Growth Rate (2013-2023)
Figure Middle East and Africa Alzheimers Disease Therapeutics Revenue (Million USD) and Growth Rate (2013-2023)
Figure Global Alzheimers Disease Therapeutics Revenue (Million USD) and Growth Rate (2013-2023)
Table F. Hoffmann-La Roche Basic Information, Manufacturing Base and Competitors
Table F. Hoffmann-La Roche Alzheimers Disease Therapeutics Type and Applications
Table F. Hoffmann-La Roche Alzheimers Disease Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
Table Merck Basic Information, Manufacturing Base and Competitors
Table Merck Alzheimers Disease Therapeutics Type and Applications
Table Merck Alzheimers Disease Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
Table Pfizer Basic Information, Manufacturing Base and Competitors
Table Pfizer Alzheimers Disease Therapeutics Type and Applications
Table Pfizer Alzheimers Disease Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
Table Novartis Basic Information, Manufacturing Base and Competitors
Table Novartis Alzheimers Disease Therapeutics Type and Applications
Table Novartis Alzheimers Disease Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
Table Eisai Basic Information, Manufacturing Base and Competitors
Table Eisai Alzheimers Disease Therapeutics Type and Applications
Table Eisai Alzheimers Disease Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
Table Actavis Basic Information, Manufacturing Base and Competitors
Table Actavis Alzheimers Disease Therapeutics Type and Applications
Table Actavis Alzheimers Disease Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
Table Daiichi Sankyo Basic Information, Manufacturing Base and Competitors
Table Daiichi Sankyo Alzheimers Disease Therapeutics Type and Applications
Table Daiichi Sankyo Alzheimers Disease Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
Table Global Alzheimers Disease Therapeutics Revenue (Million USD) by Players (2013-2018)
Table Global Alzheimers Disease Therapeutics Revenue Share by Players (2013-2018)
Figure Global Alzheimers Disease Therapeutics Revenue Share by Players in 2016
Figure Global Alzheimers Disease Therapeutics Revenue Share by Players in 2017
Figure Global Top 5 Players Alzheimers Disease Therapeutics Revenue Market Share in 2017
Figure Global Top 10 Players Alzheimers Disease Therapeutics Revenue Market Share in 2017
Figure Global Alzheimers Disease Therapeutics Revenue (Million USD) and Growth Rate (%) (2013-2018)
Table Global Alzheimers Disease Therapeutics Revenue (Million USD) by Regions (2013-2018)
Table Global Alzheimers Disease Therapeutics Revenue Market Share by Regions (2013-2018)
Figure Global Alzheimers Disease Therapeutics Revenue Market Share by Regions (2013-2018)
Figure Global Alzheimers Disease Therapeutics Revenue Market Share by Regions in 2017
Figure North America Alzheimers Disease Therapeutics Revenue and Growth Rate (2013-2018)
Figure Europe Alzheimers Disease Therapeutics Revenue and Growth Rate (2013-2018)
Figure Asia-Pacific Alzheimers Disease Therapeutics Revenue and Growth Rate (2013-2018)
Figure South America Alzheimers Disease Therapeutics Revenue and Growth Rate (2013-2018)
Figure Middle East and Africa Alzheimers Disease Therapeutics Revenue and Growth Rate (2013-2018)
Table North America Alzheimers Disease Therapeutics Revenue by Countries (2013-2018)
Table North America Alzheimers Disease Therapeutics Revenue Market Share by Countries (2013-2018)
Figure North America Alzheimers Disease Therapeutics Revenue Market Share by Countries (2013-2018)
Figure North America Alzheimers Disease Therapeutics Revenue Market Share by Countries in 2017
Figure USA Alzheimers Disease Therapeutics Revenue and Growth Rate (2013-2018)
Figure Canada Alzheimers Disease Therapeutics Revenue and Growth Rate (2013-2018)
Figure Mexico Alzheimers Disease Therapeutics Revenue and Growth Rate (2013-2018)
Table Europe Alzheimers Disease Therapeutics Revenue (Million USD) by Countries (2013-2018)
Figure Europe Alzheimers Disease Therapeutics Revenue Market Share by Countries (2013-2018)
Figure Europe Alzheimers Disease Therapeutics Revenue Market Share by Countries in 2017
Figure Germany Alzheimers Disease Therapeutics Revenue and Growth Rate (2013-2018)
Figure UK Alzheimers Disease Therapeutics Revenue and Growth Rate (2013-2018)
Figure France Alzheimers Disease Therapeutics Revenue and Growth Rate (2013-2018)
Figure Russia Alzheimers Disease Therapeutics Revenue and Growth Rate (2013-2018)
Figure Italy Alzheimers Disease Therapeutics Revenue and Growth Rate (2013-2018)
Table Asia-Pacific Alzheimers Disease Therapeutics Revenue (Million USD) by Countries (2013-2018)
Figure Asia-Pacific Alzheimers Disease Therapeutics Revenue Market Share by Countries (2013-2018)
Figure Asia-Pacific Alzheimers Disease Therapeutics Revenue Market Share by Countries in 2017
Figure China Alzheimers Disease Therapeutics Revenue and Growth Rate (2013-2018)
Figure Japan Alzheimers Disease Therapeutics Revenue and Growth Rate (2013-2018)
Figure Korea Alzheimers Disease Therapeutics Revenue and Growth Rate (2013-2018)
Figure India Alzheimers Disease Therapeutics Revenue and Growth Rate (2013-2018)
Figure Southeast Asia Alzheimers Disease Therapeutics Revenue and Growth Rate (2013-2018)
Table South America Alzheimers Disease Therapeutics Revenue by Countries (2013-2018)
Table South America Alzheimers Disease Therapeutics Revenue Market Share by Countries (2013-2018)
Figure South America Alzheimers Disease Therapeutics Revenue Market Share by Countries (2013-2018)
Figure South America Alzheimers Disease Therapeutics Revenue Market Share by Countries in 2017
Figure Brazil Alzheimers Disease Therapeutics Revenue and Growth Rate (2013-2018)
Figure Argentina Alzheimers Disease Therapeutics Revenue and Growth Rate (2013-2018)
Figure Colombia Alzheimers Disease Therapeutics Revenue and Growth Rate (2013-2018)
Table Middle East and Africa Alzheimers Disease Therapeutics Revenue (Million USD) by Countries (2013-2018)
Table Middle East and Africa Alzheimers Disease Therapeutics Revenue Market Share by Countries (2013-2018)
Figure Middle East and Africa Alzheimers Disease Therapeutics Revenue Market Share by Countries (2013-2018)
Figure Middle East and Africa Alzheimers Disease Therapeutics Revenue Market Share by Countries in 2017
Figure Saudi Arabia Alzheimers Disease Therapeutics Revenue and Growth Rate (2013-2018)
Figure UAE Alzheimers Disease Therapeutics Revenue and Growth Rate (2013-2018)
Figure Egypt Alzheimers Disease Therapeutics Revenue and Growth Rate (2013-2018)
Figure Nigeria Alzheimers Disease Therapeutics Revenue and Growth Rate (2013-2018)
Figure South Africa Alzheimers Disease Therapeutics Revenue and Growth Rate (2013-2018)
Table Global Alzheimers Disease Therapeutics Revenue (Million USD) by Type (2013-2018)
Table Global Alzheimers Disease Therapeutics Revenue Share by Type (2013-2018)
Figure Global Alzheimers Disease Therapeutics Revenue Share by Type (2013-2018)
Figure Global Alzheimers Disease Therapeutics Revenue Share by Type in 2017
Table Global Alzheimers Disease Therapeutics Revenue Forecast by Type (2018-2023)
Figure Global Alzheimers Disease Therapeutics Market Share Forecast by Type (2018-2023)
Figure Global Biomarkers Revenue Growth Rate (2013-2018)
Figure Global Cholinesterase Inhibitors Revenue Growth Rate (2013-2018)
Figure Global NMDA Receptor Antagonists Revenue Growth Rate (2013-2018)
Table Global Alzheimers Disease Therapeutics Revenue by Application (2013-2018)
Table Global Alzheimers Disease Therapeutics Revenue Share by Application (2013-2018)
Figure Global Alzheimers Disease Therapeutics Revenue Share by Application (2013-2018)
Figure Global Alzheimers Disease Therapeutics Revenue Share by Application in 2017
Table Global Alzheimers Disease Therapeutics Revenue Forecast by Application (2018-2023)
Figure Global Alzheimers Disease Therapeutics Market Share Forecast by Application (2018-2023)
Figure Global Hospitals Revenue Growth Rate (2013-2018)
Figure Global Clinics Revenue Growth Rate (2013-2018)
Figure Global Alzheimers Disease Therapeutics Revenue (Million USD) and Growth Rate Forecast (2018 -2023)
Table Global Alzheimers Disease Therapeutics Revenue (Million USD) Forecast by Regions (2018-2023)
Figure Global Alzheimers Disease Therapeutics Revenue Market Share Forecast by Regions (2018-2023)
Figure North America Alzheimers Disease Therapeutics Revenue Market Forecast (2018-2023)
Figure Europe Alzheimers Disease Therapeutics Revenue Market Forecast (2018-2023)
Figure Asia-Pacific Alzheimers Disease Therapeutics Revenue Market Forecast (2018-2023)
Figure South America Alzheimers Disease Therapeutics Revenue Market Forecast (2018-2023)
Figure Middle East and Africa Alzheimers Disease Therapeutics Revenue Market Forecast (2018-2023)